<DOC>
	<DOC>NCT01082367</DOC>
	<brief_summary>This study investigated the efficacy of inhaled TOBI treatment for early infections of P. aeruginosa in paediatric patients with cystic fibrosis.</brief_summary>
	<brief_title>Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Diagnosis of cystic fibrosis Early lower respiratory tract infection with P. aeruginosa, Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics. Administration of loop diuretics within 7 days prior to study drug administration. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Tobramycin Inhalation solution</keyword>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Lung disease</keyword>
	<keyword>anti-bacterial agents</keyword>
</DOC>